Genomics-derived (Lp-PLA2) inhibitor to advance to phase III trials.

2004 JAN 1 - (NewsRx.com & NewsRx.net) -- Human Genome Sciences, Inc., (HGSI) confirmed that its partner, GlaxoSmithKline, presented phase II clinical trial results and discussed its development plan for 480848, a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, at GlaxoSmithKline R&D review meetings held for financial analysts in London and New York.

During the analyst meetings, GlaxoSmithKline disclosed it plans to advance 480848 to phase III clinical trials in 2004 and is targeting 2008 for a new drug application filing with the U.S. Food and Drug Administration (FDA).

Under the terms of an agreement signed in 1993, Human Genome Sciences is entitled to receive clinical development milestone payments and royalties for compounds discovered by GlaxoSmithKline through the use of Human Genome Sciences' technology and intellectual property. Under the agreement, Human Genome Sciences will receive a milestone payment if 480848 moves into registration, and will receive royalties if the compound is commercialized. In addition, Human Genome Sciences has an option to copromote an approved drug in the North American and European markets.

480848 will be the first genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter phase III clinical development. Two other small-molecule drugs discovered by GlaxoSmithKline using Human Genome Sciences technology that have entered into clinical development are 462795 and 659032. 659032, also an inhibitor of Lp-PLA2, is ...